Saniona’s primary drug candidate Tesomet is being developed to treat two severe rare disorders that currently lack specific therapeutic alternatives. On Friday, October 23, the company will hold an extraordinary general meeting in Malmö, which has, among other things, a new incentive program on the agenda. BioStock was able to connect via video link with the company’s chairman J Donald deBethizy to learn more about Saniona’s ambitions. During the interview, deBethizy stressed that Saniona has to offer competitive equity incentive programs in order to find and retain the best talents in the competitive US market, where the company is now establishing a strong team behind CEO Rami Levin.
See the interview below with J Donald deBethizy from BioStock’s studio at Medicon Village in Lund.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.